Literature DB >> 11308265

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

S P Jagdev1, R E Coleman, C M Shipman, A Rostami-H, P I Croucher.   

Abstract

Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4-5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11308265      PMCID: PMC2363858          DOI: 10.1054/bjoc.2001.1727

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Bisphosphonates induce breast cancer cell death in vitro.

Authors:  O Fromigue; L Lagneaux; J J Body
Journal:  J Bone Miner Res       Date:  2000-11       Impact factor: 6.741

2.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

3.  Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.

Authors:  S Derenne; M Amiot; S Barillé; M Collette; N Robillard; P Berthaud; J L Harousseau; R Bataille
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

Review 4.  What is synergy?

Authors:  M C Berenbaum
Journal:  Pharmacol Rev       Date:  1989-06       Impact factor: 25.468

Review 5.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

6.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.

Authors:  T Saarto; C Blomqvist; P Virkkunen; I Elomaa
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

7.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors:  R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

8.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

Authors:  J E Fisher; M J Rogers; J M Halasy; S P Luckman; D E Hughes; P J Masarachia; G Wesolowski; R G Russell; G A Rodan; A A Reszka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

9.  The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

Authors:  C M Shipman; P I Croucher; R G Russell; M H Helfrich; M J Rogers
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

10.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

Authors:  A H Paterson; T J Powles; J A Kanis; E McCloskey; J Hanson; S Ashley
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

View more
  85 in total

1.  Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.

Authors:  Naoki Niikura; Jun Liu; Naoki Hayashi; Shana L Palla; Yutaka Tokuda; Gabriel N Hortobagyi; Naoto T Ueno; Richard L Theriault
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.

Authors:  Jinlu Dai; Yi Lu; Chunyan Yu; Jill M Keller; Atsushi Mizokami; Jian Zhang; Evan T Keller
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 3.  Direct antitumour activity of zoledronic acid: preclinical and clinical data.

Authors:  Joaquim Bosch-Barrera; Sofía D Merajver; Javier A Menéndez; Catherine Van Poznak
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

4.  Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.

Authors:  Arne Streitbuerger; Marcel Henrichs; Helmut Ahrens; Claudia Lanvers-Kaminzky; Francois Gouin; Georg Gosheger; Jendrik Hardes
Journal:  Int Orthop       Date:  2010-10-02       Impact factor: 3.075

5.  Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.

Authors:  Ewelina Gumbarewicz; Jarogniew J Luszczki; Anna Wawruszak; Magdalena Dmoszynska-Graniczka; Aneta J Grabarska; Agata M Jarząb; Krzysztof Polberg; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

6.  The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells.

Authors:  Ryosuke Inoue; Nori-aki Matsuki; Gao Jing; Takashi Kanematsu; Kihachiro Abe; Masato Hirata
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 7.  [Bisphosphonates for malignant bone tumors].

Authors:  G Holzer
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

8.  The microenvironment matters: estrogen deficiency fuels cancer bone metastases.

Authors:  Laura E Wright; Theresa A Guise
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

Review 9.  Bisphosphonate treatment and radiotherapy in metastatic breast cancer.

Authors:  A Ugur Ural; Ferit Avcu; Yusuf Baran
Journal:  Med Oncol       Date:  2008-01-17       Impact factor: 3.064

10.  Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.

Authors:  Amanda J Schech; Armina A Kazi; Rabia A Gilani; Angela H Brodie
Journal:  Mol Cancer Ther       Date:  2013-04-25       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.